Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy.
Publication year
2007Source
Nature Clinical Practice Rheumatology, 3, 7, (2007), pp. 414-9ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Pulmonary Diseases
Radboudumc Extern
Pathology
Medical Microbiology
Journal title
Nature Clinical Practice Rheumatology
Volume
vol. 3
Issue
iss. 7
Page start
p. 414
Page end
p. 9
Subject
N4i 1: Pathogenesis and modulation of inflammation; N4i 3: Poverty-related infectious diseases; UMCN 2.1: Heart, lung and circulationAbstract
BACKGROUND: A 54-year-old man with a 22-year history of rheumatoid arthritis and an 8-year history of chronic obstructive pulmonary disease presented with dyspnea on exertion, nonproductive cough and fatigue of 1 month's duration. His medication at presentation consisted of etanercept, azathioprine, naproxen and inhaled fluticasone and salbutamol. INVESTIGATIONS: At presentation, the patient underwent physical examination, chest X-ray and high-resolution CT, blood tests, and bronchoalveolar lavage fluid analysis including auramine stains and gene sequence analysis of cultured Mycobacterium szulgai. The patient underwent minithoracotomy after 6 months, and bronchoalveolar lavage fluid analysis, culture and chest X-ray after 18 months. Further chest imaging and culture of sputum samples were performed another year later. DIAGNOSIS: Pulmonary M. szulgai infection. MANAGEMENT: Triple drug therapy with rifampicin, ethambutol hydrochloride and clarithromycin. Anti-tumor necrosis factor treatment was continued.
This item appears in the following Collection(s)
- Academic publications [227244]
- Electronic publications [108520]
- Faculty of Medical Sciences [86731]
- Open Access publications [77770]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.